Abstract P5-07-10: Progression-free survival (PFS) and overall survival (OS) in HER2-ve advanced breast cancer (ABC) patients (pts) according to the molecular subtype in the era of modern agents. Results from the GIM-13 AMBRA study
Marina Elena Cazzaniga(Azienda Ospedaliera San Gerardo), Ferdinando Riccardi(Ospedale Antonio Cardarelli), Ornella Garrone(Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo), Clara Natoli(Kliniken Essen-Mitte), Massimiliano Alù(University of Palermo), Giorgio Mustacchi(University of Trieste), Antônio Bernardo(Fondazione Salvatore Maugeri), P. Pronzato(Accademia Nazionale dei Lincei), Claudia De Angelis(University of Naples Federico II), Paolo Marchetti(Istituto Dermopatico dell'Immacolata), Alessandra Fabi(Agostino Gemelli University Polyclinic), Lorenzo Livi(European Society for Sexual Medicine), C. Taverniti(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Laura Biganzoli(Hospital of Prato), Michela Piezzo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Anna Turletti(Ospedale Martini), Sabino De Placido, Emanuela Romagnoli(Medica (Italy)), Andrea Milani(Nerviano Medical Sciences), Alessia D’Alonzo(Ospedale Policlinico San Martino), Alessandra Bologna(Azienda Sanitaria Unità Locale di Reggio Emilia), Palma Pugliese(Ospedale Sant'Anna)
Cited by 0
Related Papers
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
|Annals of Oncology|2020|1.4k
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
|Annals of Oncology|2018|1.2k